Future prospects for human genetics and genomics in drug discovery
Maya Ghoussaini, Matthew R. Nelson, Ian Dunham
Abstract
Evidence from human genetics supporting the therapeutic hypothesis increases the likelihood that a drug will succeed in clinical trials. Rare and common disease genetics yield a wide array of alleles with a range of effect sizes that can proxy for the effect of a drug in disease. Recent advances in large scale population collections and whole genome sequencing approaches have provided a rich resource of human genetic evidence to support drug target selection. As the range of phenotypes profiled increases and ever more alleles are discovered across world-wide populations, these approaches will increasingly influence multiple stages across the lifespan of a drug discovery programme.
Topics & Concepts
BiologyGenomicsDrug discoveryGeneticsDiseaseComputational biologyHuman genomePopulation geneticsPopulationGenomeEvolutionary biologyBioinformaticsGeneMedicineEnvironmental healthPathologyGenomics and Rare DiseasesGenetic Associations and EpidemiologyBioinformatics and Genomic Networks